No significant differences in recurrence rates among women with DCIS taking anastrozole or tamoxifen
(American Association for Cancer Research) Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two groups had different side effects, according to results from the phase III IBIS-II DCIS clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news
DCIS patients receiving anastrozole reported symptoms different from those receiving tamoxifen
(American Association for Cancer Research) Analysis of patient-reported outcomes (PRO), a secondary endpoint of the phase III, NSABP B-35 clinical trial, in which anastrazole and tamoxifen were compared in postmenopausal women with ductal carcinoma in-situ (DCIS) who underwent lumpectomy plus radiotherapy, found that there were no differences in outcomes related to quality of life but some differences in outcomes related to symptoms in the two treatment groups, according to data presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news
Breast Cancer Survival Improved With Arimidex (CME/CE)
(MedPage Today) -- But aromatase inhibitor may not best tamoxifen in older women (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 2, 2015 Category: Geriatrics Source Type: news
ASCO: Arimidex Ups 10-Year Survival Rate in DCIS (CME/CE)
(MedPage Today) -- But aromatase inhibitor may not best tamoxifen in older women (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 1, 2015 Category: Geriatrics Source Type: news
Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer
Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. The benefit reported in this trial appeared later in follow up of the women in the study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 1, 2015 Category: Science Source Type: news
Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer
(Loyola University Health System) Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. These findings were presented today at the 2015 ASCO Annual Meeting in Chicago. The benefit reported in this trial appeared later in follow up of the women in the study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2015 Category: Cancer & Oncology Source Type: news
Some 'Benign' Breast Masses Pose Greater Cancer Risk Than We Thought
By Gene Emery (Reuters Health) - A type of "benign" mass found in the breast tissue of about 100,000 U.S. women each year poses a greater risk of cancer than previously thought, according to a new review. The mass is classified as atypical hyperplasia, or atypia. Most women who have it - and one out of 10 women who have a breast biopsy do - are usually told that their test result was benign, even though their cells seemed to be exhibiting some early characteristics of a tumor. Doctors may tell those women that they face an above-average risk of cancer so they need to be ...
Source: Healthy Living - The Huffington Post - December 31, 2014 Category: Consumer Health News Source Type: news
Fulvestrant Survival Advantage in Advanced Breast CancerFulvestrant Survival Advantage in Advanced Breast Cancer
New survival data from the FIRST trial show a survival advantage for the injectable fulvestrant over the standard of care, oral anastrozole. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
anastrozole (Arimidex)
Title: anastrozole (Arimidex)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 10/3/2014 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 3, 2014 Category: Drugs & Pharmacology Source Type: news
One million women denied 7p breast cancer drug that can halve chance of developing disease
One million women have been denied pills that could reduce chances of developing breast cancer. Tamoxifen, Raloxifene and Anastrozole have not been licensed for preventative use. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news
One million women denied the 7p breast cancer drug that can halve chance of developing disease because of red tape
One million women have been denied pills that could reduce chances of developing breast cancer. Tamoxifen, Raloxifene and Anastrozole have not been licensed for preventative use. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news
Arimidex – Anastrozole – Aromatase...
Arimidex helps prevent the production of estrogen, a hormone that fuels many breast cancer tumors. It is considered a hormonal treatment, and can help prevent recurrence of breast cancer in postmenopausal women. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - May 5, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Arimidex: Top Drug for Breast Ca Prevention?
SAN ANTONIO (MedPage Today) -- Should anastrozole (Arimidex) be the first choice in pharmacologic primary prevention of breast cancer, based on IBIS-II trial results presented here? No, said most experts. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 17, 2013 Category: Hematology Source Type: news
Exercise can reduce drug-related joint pain in breast cancer patients, study shows
Breast cancer survivors taking aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.Five years of AI use after surgery or other primary treatment is recommended for postmenopausal women diagnosed with stages 1-3 hormone receptor-positive breast cancers, which account for nearly 70 percent of all newly diagnosed breast cancer cases. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 17, 2013 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news
Antihormone therapy anastrozole may provide new option for breast cancer prevention (EurekAlert, 12 December 2013)
Data from the International Breast Cancer Intervention Study II (IBIS-II) Prevention trial presented at the 2013 San Antonio Breast Cancer Symposium, and published in The Lancet, investigates the use of aromatase inhibitor anastrozole in the prevention of hormone receptor-positive breast cancer in high risk women.
Full article (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 13, 2013 Category: Endocrinology Source Type: news
